Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nasdaq  >  Amgen, Inc.    AMGN

SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector newsTweets 

Amgen, Inc. : A Tribute to George Rathmann, Amgen's Founding CEO (1927-2012)

share with twitter share with LinkedIn share with facebook
share via e-mail
0
04/24/2012 | 04:55am CEST

THOUSAND OAKS, Calif., April 23, 2012 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that George Rathmann, founding CEO of Amgen from 1980 to 1988 and board chairman until 1990, has passed away.

Recruited by Bill Bowes, one of Amgen's founders, Rathmann possessed the kind of passion and charisma that helped build the company and attract world-class scientific talent. Regarded as one of the founding fathers of biotechnology, George had the vision to see how biotechnology could transform the practice of medicine with the mix of business and science to bring that vision to life. One of Rathmann's chief accomplishments was finding the funds Amgen needed during its start-up years. Nicknamed the "Golden Throat" by friends who admired his persuasiveness, he secured venture capital, built revenue streams through partnerships, and guided Amgen through its first public offerings.

"George Rathmann was a biotechnology giant and we were privileged to have him as our first CEO. George's vision and values are as alive today at Amgen as they were when he led the Company," said Kevin Sharer, Chairman and CEO of Amgen. "Bob Bradway, our next CEO, and I both share George's commitment to patients and conviction that being science-based is the best foundation for innovation in biotechnology."

Through the years, Amgen has continued to recognize the significant impact Rathmann made on the Company. In 2004, a full-size sculpture of Rathmann was dedicated on Amgen's campus in recognition of his leadership. In 2005, Amgen created the annual George B. Rathmann Award, the company's highest honor, to recognize staff members who exemplify Amgen's standards of excellence to advance Amgen's mission to serve patients.

Rathmann was recognized as BIO's CEO of the year in 1987 and 1988. Upon leaving Amgen, Rathmann became CEO and chairman of Seattle-based biotech ICOS Corporation (later acquired by Eli Lilly). He later served as CEO and chairman of genomics company Hyseq, Inc.

About Amgen
Amgen discovers, develops, manufactures and delivers innovative human therapeutics. A biotechnology pioneer since 1980, Amgen was one of the first companies to realize the new science's promise by bringing safe, effective medicines from lab to manufacturing plant to patient. Amgen therapeutics have changed the practice of medicine, helping millions of people around the world in the fight against cancer, kidney disease, rheumatoid arthritis, bone disease and other serious illnesses. With a deep and broad pipeline of potential new medicines, Amgen remains committed to advancing science to dramatically improve people's lives. To learn more about our pioneering science and vital medicines, visit www.amgen.com. Follow us on www.twitter.com/amgen.

CONTACT: Amgen, Thousand Oaks
Christine Regan, 805-447-5476 (media)

(Logo: http://photos.prnewswire.com/prnh/20081015/AMGENLOGO)

SOURCE Amgen

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on AMGEN, INC.
05/26 Khang & Khang LLP Announces an Investigation of Amgen Inc. and Encourages Inv..
05/26 GLANCY PRONGAY & MURRAY LLP : Commences Investigation on Behalf of Amgen Inc. In..
05/24 AMGEN : Health and Human Services Department (HHS); Food and Drug Administration..
05/23 Lundin Law PC Announces an Investigation of Amgen Inc. and Advises Investors ..
05/23 Bronstein, Gewirtz & Grossman, LLC Announces Investigation of Amgen Inc. (AMG..
05/23 NEUROPACE : Develops and markets implantable devices for the treatment of neurol..
05/23 AMGEN, INC. : Blog Coverage: Amgen Announces New Data from the FOURIER Trial
05/23 AMGEN : shares fall as it reveals new cardiovascular risks for its Evenity osteo..
05/22 Goldberg Law PC Announces an Investigation of Amgen Inc.
05/22 AMGEN INC : Change in Directors or Principal Officers, Submission of Matters to ..
More news
Sector news : Bio Therapeutic Drugs
05/23 UK competition watchdog accuses Merck of obstructing biosimilars
05/22 Cross-border M&A between U.S. and European firms at 10 year high
05/09 Sanofi pegs U.S. drug price rises to below healthcare inflation
05/09DJVERTEX PHARMACEUTICALS INCORPORATED : Trump's Pick to Lead FDA Has Backing of Bi..
05/07 REGENERON SHARES POISED FOR REBOUND : Barron's
More sector news : Bio Therapeutic Drugs
News from SeekingAlpha
05/27 3 THINGS IN BIOTECH YOU SHOULD LEARN : May 27, 2017
05/26 Renal Cancer Data For Acceleron's And Coherus' Biosimilars' Date With The FDA
05/25 FDA advisory committee backs Pfizer's Epogen biosimilar
05/25 FDA drug approvals rebound from last year, up over 100% yoy
05/25 Ad Comm review today for Pfizer's biosimilar to Amgen's Epogen